Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walid Fakhouri

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Journal of Health Economics and Outcomes Research|July 21, 2020
A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to MethotrexateWalid Fakhouri, Xiaofei Wang, Inmaculada de La Torre, et al.
Mathematical Biosciences|February 21, 2012
A two-scale mathematical model for DNA transcriptionChichia Chiu, Walid Fakhouri, Nianzheng Liu, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 27, 2019
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in SpainMax Schlueter, Elaine Finn, Silvia Díaz, et al.
Biochemistry and Molecular Biology Education : a Bimonthly Publication of the International Union of Biochemistry and Molecular Biology|August 24, 2024
Addition of an audience response system in a biomedical science course improves learning environment and student performanceNeha Parikh, Emily Hansen-Kiss, Walid Fakhouri, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 28, 2020
A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritisMax Schlueter, Peter Rouse, Ashley Pitcher, et al.
BMC Cancer|July 19, 2025
Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational studyJudy King, Walid Fakhouri, Rosalind Jarvis, et al.
Journal of Health Economics and Outcomes Research|June 27, 2025
Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry DataHeidi Loponen, Juha Mehtälä, Laila Mehkri, et al.
Rheumatology Advances in Practice|September 23, 2020
The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling studyJames Galloway, Jean-Philippe Capron, Francesco De Leonardis, et al.
RMD Open|December 11, 2021
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to targetPeter C Taylor, Mart Van de Laar, Andrew Laster, et al.
Rheumatology and Therapy|July 20, 2020
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on BaricitinibValentina Perrone, Serena Losi, Veronica Rogai, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of Health Economics and Outcomes Research|July 21, 2020
A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to MethotrexateWalid Fakhouri, Xiaofei Wang, Inmaculada de La Torre, et al.
Mathematical Biosciences|February 21, 2012
A two-scale mathematical model for DNA transcriptionChichia Chiu, Walid Fakhouri, Nianzheng Liu, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 27, 2019
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in SpainMax Schlueter, Elaine Finn, Silvia Díaz, et al.
Biochemistry and Molecular Biology Education : a Bimonthly Publication of the International Union of Biochemistry and Molecular Biology|August 24, 2024
Addition of an audience response system in a biomedical science course improves learning environment and student performanceNeha Parikh, Emily Hansen-Kiss, Walid Fakhouri, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 28, 2020
A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritisMax Schlueter, Peter Rouse, Ashley Pitcher, et al.
BMC Cancer|July 19, 2025
Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational studyJudy King, Walid Fakhouri, Rosalind Jarvis, et al.
Journal of Health Economics and Outcomes Research|June 27, 2025
Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry DataHeidi Loponen, Juha Mehtälä, Laila Mehkri, et al.
Rheumatology Advances in Practice|September 23, 2020
The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling studyJames Galloway, Jean-Philippe Capron, Francesco De Leonardis, et al.
RMD Open|December 11, 2021
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to targetPeter C Taylor, Mart Van de Laar, Andrew Laster, et al.
Rheumatology and Therapy|July 20, 2020
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on BaricitinibValentina Perrone, Serena Losi, Veronica Rogai, et al.
Pageof 3